Isocitrate Dehydrogenase 2 Gene

• The Isocitrate Dehydrogenase 2 Gene (IDH2) encodes an enzyme essential for the Krebs cycle and cellular energy production.
• IDH2 catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, producing NADPH.
• Mutations in the IDH2 gene lead to the production of an oncometabolite, 2-hydroxyglutarate (2-HG).
• These mutations are frequently observed in several types of cancer, including acute myeloid leukemia and gliomas.
• Targeting mutant IDH2 has emerged as a therapeutic strategy in specific cancers.

What is Isocitrate Dehydrogenase 2 Gene (IDH2)?

The Isocitrate Dehydrogenase 2 Gene (IDH2) is a gene that provides instructions for making an enzyme called isocitrate dehydrogenase 2. This enzyme is primarily located in the mitochondria, the powerhouses of the cell, where it plays a critical role in cellular respiration and metabolism. Specifically, IDH2 is involved in the Krebs cycle (also known as the citric acid cycle), a central metabolic pathway that generates energy for the cell. The enzyme is one of three isocitrate dehydrogenases found in humans, with IDH1 and IDH3 being the other two, each having distinct cellular locations and functions.

IDH2 catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), a key intermediate in the Krebs cycle. This reaction also produces NADPH (nicotinamide adenine dinucleotide phosphate), a crucial molecule for various cellular processes. NADPH is vital for maintaining redox balance, protecting cells from oxidative stress, and supporting biosynthetic pathways, including lipid synthesis. The proper functioning of IDH2 is therefore essential for overall cellular health and metabolic regulation.

The Role and Function of Isocitrate Dehydrogenase 2 Gene

The primary Isocitrate Dehydrogenase 2 gene function is to encode the mitochondrial enzyme IDH2, which is central to energy metabolism and redox homeostasis. As part of the Krebs cycle, IDH2 converts isocitrate into alpha-ketoglutarate. This conversion is significant not only for energy production but also for generating NADPH. NADPH is a powerful reducing agent, indispensable for several cellular processes, including:

• Maintaining redox balance within the cell.
• Protecting cells from oxidative stress by supporting antioxidant enzymes.
• Supporting biosynthetic pathways, such as lipid synthesis.

The proper functioning of IDH2 is therefore essential for overall cellular health and metabolic regulation. Beyond its role in the Krebs cycle, IDH2 contributes to the broader metabolic landscape by influencing epigenetic regulation. Alpha-ketoglutarate, the product of IDH2 activity, is a co-factor for several dioxygenase enzymes, including those involved in DNA and histone demethylation. These enzymes are crucial for gene expression regulation and maintaining cellular identity. Therefore, disruptions in IDH2 activity can have far-reaching consequences, affecting not only energy metabolism but also gene expression patterns and cellular differentiation.

IDH2 Gene Mutations and Their Link to Cancer

Mutations in the IDH2 gene are frequently observed in various types of cancer, profoundly altering cellular metabolism and contributing to oncogenesis. The most common IDH2 gene mutation effects involve specific amino acid substitutions, such as R140Q or R172K, which confer a neomorphic enzymatic activity. Instead of producing alpha-ketoglutarate, mutant IDH2 enzymes catalyze the reduction of alpha-ketoglutarate to 2-hydroxyglutarate (2-HG), an oncometabolite. Elevated levels of 2-HG can inhibit several alpha-ketoglutarate-dependent dioxygenases, including TET (Ten-Eleven Translocation) DNA demethylases and histone demethylases.

This inhibition leads to widespread epigenetic alterations, such as hypermethylation of DNA and histones, which can silence tumor suppressor genes and promote uncontrolled cell proliferation. The IDH2 gene role in cancer is particularly well-established in acute myeloid leukemia (AML), where IDH2 mutations are found in approximately 8-19% of cases, according to the American Cancer Society. They are also prevalent in certain gliomas, chondrosarcomas, and cholangiocarcinomas. The presence of IDH2 mutations often defines distinct clinical subgroups of these cancers, influencing prognosis and treatment responses.

The discovery of these mutations has led to the development of targeted therapies, such as enasidenib, which specifically inhibit mutant IDH2 enzymes. These inhibitors aim to reduce 2-HG levels, reverse epigenetic dysregulation, and restore normal cellular differentiation, offering a promising avenue for patients with IDH2-mutated cancers.